The impact of the obesity epidemic in America is reflected in increasing rates of Type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), as well as poorer outcomes with the COVID-19 pandemic. While lifestyle modification remains a cornerstone of improved outcomes for patients suffering from obesity, it requires more engagement on the part of patients and the healthcare community. Part of the solution lies in leveraging technological advances to facilitate new ways of engaging patients, such as assessing liver health with FibroScan®, which can be integral to cost effectively improving outcomes of lifestyle modification.
To this point, gastroenterology practices are discovering the multiple benefits of the MetaPhy Health CCM program which integrates FibroScan® non-invasive technology into its CCM liver disease programs. FibroScan® rapidly examines liver stiffness and fat at the point of care and addresses Type 2 diabetes and obesity. This approach to CCM validates results, improves patient outcomes, reduces costs associated with liver disease and, concurrently, strengthens a practice’s financial performance.
Addressing the Leading Causes of Liver Disease
NALFD and nonalcoholic steatohepatitis (NASH) are highly prevalent in people living with metabolic syndrome (MetS). They are also key contributors to increased cardiovascular disease (CVD) mortality among people living with Type 2 diabetes.
Given these factors, gastroenterology practices can build out an ancillary CCM program to address liver disease and successfully integrate FibroScan® capabilities with the MetaPhy CCM model. This allows them to provide services to patients across the spectrum of NAFLD, leveraging FibroScan® to monitor and engage patients.
NAFLD and NASH are tightly intertwined with obesity, diabetes and lifestyle, requiring more coordinated engagement to support behavioral changes that will result in better outcomes across the co-morbid conditions affecting the individual patient and the course of liver disease
At the Forefront of Battle Against Liver Disease
Gastroenterology practices are at the forefront of managing NAFLD and NASH, and CCM provides the opportunity to cost-effectively improve that coordination. Gastroenterologists can change the game for these underserved patients with the exceptional ancillary of FibroScan® and MetaPhy’s effective CCM program to create healthcare pathways that will improve outcomes, save lives and, in these challenging times, begin income repair for their practices.
NAFLD has become the most common chronic liver disease in the world and affects between 25% to 30% of adults in the United States. About 20% of patients with NAFLD will progress to NASH, with around one-quarter of those developing liver fibrosis.
The traditional approach of telling a patient that they need to alter their lifestyle has not been adequate. Most patients want to change but may face barriers or challenges to achieving this in a meaningful and sustainable way. Our chronic care disease management programs engage the patient to better understand their situation and tailor a plan that helps address their circumstances with high touch and compassionate care.